This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Aptar Pharma discusses intranasal administration for CNS therapeutics
Webinars, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
New solutions for pre-clinical discovery in respiratory healthcare
Webinars, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions
Improving Intranasal Sprays for Respiratory Viral Infections
Publications, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Product Solutions
The Go-To Drug Delivery Expert
Brochures, Pharmaceutical, Brand Differentiation, Product Solutions, Sustainability, Drug Delivery Innovations
